Using thoracic ultrasonography to guide pleurodesis leads to shorter hospital stays, with similar success rates, compared with standard care in people with malignant pleural effusion, SIMPLE study findings indicate.
Truncating TP53 mutations are associated with shorter survival in people with localized non-small-cell lung cancer while mutations in KEAP1 are linked to poor outcomes in both localized and advanced disease, German researchers report.
The overall survival advantage offered by the use of durvalumab alongside first-line chemotherapy in people with extensive-stage small-cell lung cancer is sustained over time, suggests the 3-year follow-up of the CASPIAN study.
Trastuzumab deruxtecan achieves durable responses in individuals who have received prior treatment for metastatic non-small-cell lung cancer harboring HER2 mutations, suggests the DESTINY-Lung01 trial.
Individuals with unresectable locally advanced non-small-cell lung cancer and no progression after chemoradiotherapy could benefit from the addition of the CD73 inhibitor oleclumab or the NKG2A-targeted agent monalizumab to consolidation durvalumab, suggest phase 2 results.
The addition of bevacizumab to erlotinib does not improve the overall survival of treatment-naïve patients with advanced non-small-cell lung cancer harboring an activating EGFR mutation, NEJ026 study data show.
Strategies to improve flexibility in clinical trials may improve enrollment rates during and after the COVID-19 pandemic, according to a study presented at the IASLC 2021 World Conference on Lung Cancer.
Assessing circulating tumor DNA levels prior to initiating neoadjuvant chemoimmunotherapy for locally advanced non-small-cell lung cancer could help to identify patients likely to derive long-term benefit from treatment, suggest exploratory data.
Treatment with carboplatin and pemetrexed plus atezolizumab shows promise for people with nonsquamous non-small-cell lung cancer and asymptomatic, untreated brain metastases, phase 2 study findings indicate.
The ATLANTIS trial has found no significant overall survival improvement with the combination of lurbinectedin and doxorubicin versus chemotherapy in previously treated patients with small-cell lung cancer.
Stereotactic ablative body radiotherapy offers similar outcomes, in terms of toxicity and efficacy, whether it is given as a single fraction or in multiple fractions to patients with up to three lung oligometastases, SAFRON II trial data show.